ATE342509T1 - Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau - Google Patents

Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Info

Publication number
ATE342509T1
ATE342509T1 AT01909655T AT01909655T ATE342509T1 AT E342509 T1 ATE342509 T1 AT E342509T1 AT 01909655 T AT01909655 T AT 01909655T AT 01909655 T AT01909655 T AT 01909655T AT E342509 T1 ATE342509 T1 AT E342509T1
Authority
AT
Austria
Prior art keywords
tau
phospho
diagnosis
tauopathies
ratio
Prior art date
Application number
AT01909655T
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE342509T1 publication Critical patent/ATE342509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
AT01909655T 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau ATE342509T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00870008 2000-01-24
US17839100P 2000-01-27 2000-01-27
EP00870280 2000-11-22

Publications (1)

Publication Number Publication Date
ATE342509T1 true ATE342509T1 (de) 2006-11-15

Family

ID=27223742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909655T ATE342509T1 (de) 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Country Status (13)

Country Link
US (2) US6680173B2 (de)
EP (1) EP1250600B1 (de)
JP (1) JP5247963B2 (de)
AT (1) ATE342509T1 (de)
AU (1) AU777837B2 (de)
BR (1) BR0107851A (de)
CA (1) CA2397991C (de)
CY (1) CY1107993T1 (de)
DE (2) DE60123752T2 (de)
DK (1) DK1250600T3 (de)
ES (1) ES2274869T3 (de)
HK (1) HK1048513B (de)
WO (1) WO2001055725A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4681175B2 (ja) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 播種性血管内凝固症候群及びその発症前段階を検出する方法
ES2352668T3 (es) * 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
CA2519499A1 (en) * 2003-03-12 2004-09-23 Assay Designs, Inc. Phosphokinase assay
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
US8642543B2 (en) * 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
JP5681719B2 (ja) 2009-09-24 2015-03-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル タウ機能不全を伴う神経障害を処置するための新規な治療ターゲットとしてのｆｋｂｐ５２−タウ相互作用
WO2011109112A2 (en) * 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
US20130052669A1 (en) * 2010-04-30 2013-02-28 Amanda G. Paulovich Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
PE20150646A1 (es) * 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
WO2014039630A2 (en) 2012-09-05 2014-03-13 Emory University Diagnostic testing in dementia and methods related thereto
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2800827T3 (es) 2013-06-10 2021-01-04 Ipierian Inc Procedimientos de tratamiento de una tauopatía
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015157390A1 (en) * 2014-04-08 2015-10-15 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
DE102014013571A1 (de) * 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
KR102033776B1 (ko) * 2017-10-31 2019-10-17 가천대학교 산학협력단 타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법
CA3093200A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
CN113166235A (zh) * 2018-11-22 2021-07-23 富士瑞必欧株式会社 抗体偶联物
JP2022527087A (ja) * 2019-03-28 2022-05-30 ハー・ルンドベック・アクチエゼルスカベット タウオパチーを診断するためのｐＳ３９６アッセイの使用
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2021014473A (es) * 2019-05-31 2022-01-06 Lilly Co Eli Compuestos y metodos dirigidos a la tau humana.
WO2021157634A1 (ja) * 2020-02-05 2021-08-12 大日本住友製薬株式会社 タウオパチーおよび認知症関連疾患の判定薬および判定方法
KR20240134175A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
DE69318420T2 (de) * 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
DK0737208T3 (da) * 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
EP0772634B1 (de) * 1994-07-29 2003-03-12 Innogenetics N.V. Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1999062548A1 (en) * 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies

Also Published As

Publication number Publication date
CA2397991A1 (en) 2001-08-02
HK1048513A1 (en) 2003-04-04
US6680173B2 (en) 2004-01-20
JP5247963B2 (ja) 2013-07-24
EP1250600A2 (de) 2002-10-23
AU777837B2 (en) 2004-11-04
US20030194742A1 (en) 2003-10-16
WO2001055725A2 (en) 2001-08-02
AU3731901A (en) 2001-08-07
DE60123752D1 (de) 2006-11-23
BR0107851A (pt) 2002-10-29
CA2397991C (en) 2017-10-24
DE1250600T1 (de) 2003-03-06
WO2001055725A3 (en) 2001-12-20
US7387879B2 (en) 2008-06-17
CY1107993T1 (el) 2013-09-04
US20040091942A1 (en) 2004-05-13
DE60123752T2 (de) 2007-08-23
JP2003521499A (ja) 2003-07-15
DK1250600T3 (da) 2007-02-05
EP1250600B1 (de) 2006-10-11
HK1048513B (en) 2007-12-07
ES2274869T3 (es) 2007-06-01

Similar Documents

Publication Publication Date Title
ATE342509T1 (de) Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
NO973444L (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
ATE394658T1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
ATE406578T1 (de) Candida-nachweis
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
DE69928809D1 (de) Differentielle diagnose von neurodegeneration
WO2003008933A3 (en) Test strip for a lateral flow assay
BR9710836A (pt) Ensaio de analitos usando marcas em partìculas
WO2002046746A3 (en) Method for detection of vitamin d metabolites
EP1461061A4 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von krankheiten und zuständen im zusammenhang mit chemokine-rezeptoren
ATE540319T1 (de) Verfahren für die bestimmung von fk506
DE60239552D1 (de) Messung der protein-syntheseraten bei menschen und in experimentellen systemen durch verwendung von isotopisch markiertem wasser
DE60117592D1 (de) Diagnose von pre-eclampsia
KR950018482A (ko) 혈소판 응집 측정방법
WO2004094675A3 (en) Compositions and methods for determining the presence of sars coronavirus in a sample
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
ES2068599T3 (es) Procedimiento de reduccion de interferencias en un dosificado por fluorescencia.
NO953770L (no) Analysemetode
FI20011168A0 (fi) Menetelmä infektion laadun määrittämiseksi
WO2002059600A3 (en) Analyte detection
DE60012140D1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
WO2004029216A3 (en) Diagnosis of invasive mold infection
ATE349702T1 (de) Nachweis und quantifizierung von cripto-1
DE60236849D1 (de) Diagnose von atherosclerose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250600

Country of ref document: EP